Letermovir (Prevymis®)

Assessment Status Assessment process complete
Drug Letermovir
Brand Prevymis®
Indication For the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).
Assessment Process
Rapid review commissioned 12/03/2018
Rapid review completed 10/05/2018
Rapid review outcome Full Pharmacoeconomic Assessment Recommended.
Full pharmacoeconomic assessment commissioned by HSE 29/05/2018
Pre-submission consultation with Applicant 09/07/2018
Full submission received from Applicant 02/04/2019
Preliminary review sent to Applicant 29/08/2019
NCPE assessment re-commenced 27/09/2019
Follow-up to preliminary review sent to Applicant 25/11/2019
NCPE assessment re-commenced 05/12/2019
Factual accuracy sent to Applicant 24/04/2020
NCPE assessment re-commenced 01/05/2020
NCPE assessment completed 19/05/2020
NCPE assessment outcome The NCPE recommends that letermovir be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Technical Summary

Plain English Summary

The HSE has approved reimbursement following confidential price negotiations March 2021.